Jci_page_head_homepage_01 Jci_page_head_homepage_02
David M. Selva, Kevin N. Hogeveen, Sheila M. Innis, Geoffrey L. Hammond
Published in Volume 117, Issue 12
J Clin Invest. 2007; 117(12):3979–3987 doi:10.1172/JCI32249
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2
Insulin does not influence SHBG production by HepG2 cells.

(AD) HepG2 cells were cultured in serum-free medium, inactivated FBS, or untreated FBS for 5 days and treated daily with insulin at different concentrations. Accumulation of human SHBG in the medium was measured at timed intervals using an immunofluorometric assay (46) over a 5-day treatment period. Data points are shown as mean ± SD of triplicates; *P < 0.05, **P < 0.01 compared with no insulin treatment (AC). On day 5 cells were taken for human SHBG mRNA and cyclophilin A mRNA measurements by RT-PCR analyses (D). (E) The effect of insulin (12 μg/ml) on human SHBG promoter activity was analyzed in HepG2 cells in the context of a luciferase reporter gene assay. Data points are mean ± SD of triplicate measurements.